ReviewNeurology2010
Monoclonal antibodies in MS: mechanisms of action.
Review in Neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.The Cochrane database of systematic reviews · 2017Pooled it
- The CNS Meninges and the Synovial Joint: Parallel Immunological Structures in Autoimmune Disease.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Antigen-Specific Inverse Vaccination Strategies Using Particle Systems for Multiple Sclerosis.ACS biomaterials science & engineering · 2026Review
- Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis.Frontiers in immunology · 2026Observational
- T cell-mediated immunodysregulation in multiple sclerosis: from pathogenic subsets to therapeutic advances.Frontiers in immunology · 2026Review
- People with Primary Progressive Multiple Sclerosis Have a Lower Number of Central Memory T Cells and HLA-DRCells · 2023Article
- Decreased Neurofilament L Chain Levels in Cerebrospinal Fluid and Tolerogenic Plasmacytoid Dendritic Cells in Natalizumab-Treated Multiple Sclerosis Patients - Brief Research Report.Frontiers in cellular neuroscience · 2021Article
- Review
- Daclizumab Therapy for Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019Review
- Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects.Frontiers in neurology · 2018Article
- Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.Molecular neurobiology · 2017Article
- Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Article
- Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Expert opinion on biological therapy · 2016Review
- Spotlight on daclizumab: its potential in the treatment of multiple sclerosis.Degenerative neurological and neuromuscular disease · 2016Review
- An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations.Patient preference and adherence · 2015Review
- Achieving Remission in Gulf War Illness: A Simulation-Based Approach to Treatment Design.PloS one · 2015Article
- Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.JAMA neurology · 2015Article
- Article
- Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Journal of central nervous system disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of multiple sclerosis (MS). mAbs target selective molecules and have shown early promise, along with notable risks, in the treatment of MS and other immune-mediated diseases. The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.